Abivax announces closing of its initial public offering on the nasdaq global market

Paris, france / accesswire / october 24, 2023 / abivax sa (euronext paris:fr0012333284 - abvx) (" abivax " or the " company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the closing of its previously announced initial public offering on the nasdaq global market by way of a capital increase of 20,325,500 new ordinary shares (the " new shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of american depositary shares (" adss "), each representing the right to receive one ordinary share, in the united states (the " u.s. offering ") and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the united states to certain investors (the " european private placement " and together with the u.s. offering, the " global offering "). the offering price was set at $11.60 per ads in the u.s. offering and a corresponding offering price of €10.9864 per ordinary share in the european private placement.
ABVX Ratings Summary
ABVX Quant Ranking